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scattered APOBEC-induced mutations.
This distribution should be taken into
account in efforts to identify genes
significantly mutated in cancer as well as
in models of cancer mutagenesis.
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An antiviral component of the human innate immune
system—the APOBEC cytidine deaminases—was
recently identified as a prominent source of muta-
tions in cancers. Here, we investigated the distri-
bution of APOBEC-induced mutations across the
genomes of 119 breast and 24 lung cancer samples.
While the rate of most mutations is known to be
elevated in late-replicating regions that are charac-
terized by reduced chromatin accessibility and low
gene density, we observed a marked enrichment
of APOBEC mutations in early-replicating regions.
This unusual mutagenesis profile may be associated
with a higher propensity to form single-strand DNA
substrates for APOBEC enzymes in early-replicating
regions and should be accounted for in statistical
analyses of cancer genome mutation catalogs aimed
at understanding the mechanisms of carcinogenesis
as well as highlighting genes that are significantly
mutated in cancer.INTRODUCTION
Recent advances in sequencing of human cancer genomes have
implicated a subfamily of the human APOBEC (apolipoprotein B
mRNA editing enzyme, catalytic polypeptide-like) cytidine de-
aminases in cancermutagenesis (Nik-Zainal et al., 2012; Roberts
et al., 2012). Normally, APOBECs function to restrict retroviruses
and retrotransposons via deamination of cytidines, resulting in
hypermutation or degradation of the retroelement’s single-
stranded DNA replication intermediate (Refsland and Harris,
2013). However, APOBECs can also mutate a host’s DNA
when it persists in single-stranded form, likely resulting in the sig-
nificant number of apparent APOBEC-induced mutationsCell Repobserved in many types of human cancer (Alexandrov et al.,
2013; Burns et al., 2013; Roberts et al., 2013).The conclusion
that one or multiple APOBECs induced these mutations was
supported by the mutations’ observed tendency to occur in
clusters in a strand-coordinated fashion (Alexandrov et al.,
2013; Nik-Zainal et al., 2012; Roberts et al., 2012, 2013) and by
a high enrichment of the APOBEC mutagenesis signature,
TCW/TTW or TCW/TGW (mutated nucleotide underlined,
W = A or T), among clustered as well as scattered mutations.
The strand-coordinated clusters observed in these studies
agreed with the expected pattern of mutations caused by an
APOBEC acting processively on a long single-stranded DNA
(ssDNA) substrate, where cytidine deaminations can only occur
on the same DNA strand. Unlike in mutation clusters, scattered
mutations could be caused by APOBEC-induced cytidine deam-
ination in shorter ssDNA stretches. The origin of the ssDNA sub-
strates for APOBECmutagenesis in cancer genomes is still to be
determined (reviewed in Roberts and Gordenin, 2014). The main
difficulty in this task is the complexity and variability of environ-
mental and genetic factors that influence the accumulation of
mutations over the lifetime of cancer.
One useful approach toward understanding mutagenesis in
cancer emerged recently due to the progress of the Epigenome
Roadmap and ENCODE projects (Kellis et al., 2014; Raney et al.,
2011). The genome-wide distributions of multiple epigenomic
features, such as replication timing, chromatin accessibility,
and transcription, were determined and cataloged for cell lines
originating from different human tissue types. The distributions
of these features subsequently proved to be good predictors
of regional differences in mutation density in cancers originated
from the same tissues (Lawrence et al., 2013; Polak et al., 2015).
The profiling of mutations in cancer genomes against these epi-
genomic features can guide future research of mutagenic mech-
anisms in model systems and also help in dissecting the relative
roles of mutagenesis and selection in the accumulation of cancer
driver and passenger mutations (Lawrence et al., 2013; Polak
et al., 2014).orts 13, 1103–1109, November 10, 2015 ª2015 The Authors 1103
Figure 1. The Distribution of APOBEC-
Signature Mutation Clusters Relative to Epi-
genomic Features in Cancer Genomes
See Figure S1 and text for defining the subgroup of
clusters used in this analysis.
(A–D) The distribution of C- or G-strand coordi-
nated clusters with at least three mutations relative
to DNA replication timing in lung (A) and breast (B)
cancer genomes and relative to chromatin acces-
sibility in lung (C) and breast (D) cancer genomes.
Bins on the horizontal axis were obtained by sort-
ing all genome positions by the values of the
genomic feature (DNA replication time or chro-
matin accessibility) and dividing into four non-
overlapping, equal-sized windows. The deviation
from the uniform distribution of clusters in genomic
space was confirmed by Cochran-Armitage test
(the p values were calculated under the null hy-
pothesis that all bins would contain an equal
fraction of clusters).Here, we analyzed the genomic localization of both clustered
and scattered APOBEC mutations across lung and breast
cancer genomes and their correlation with the location of
epigenomic features, including replication timing, chromatin
accessibility, and transcription. We found that the relationship
between the location of APOBEC-induced mutations and these
epigenomic features is reversed compared to other mutation
types.
RESULTS
Mutation Clusters Enriched with APOBEC-Signature
Mutations Are More Frequent in Early-Replicating
Regions
We assessed the trinucleotide sequence context and base sub-
stitution of each mutation in 24 lung (Imielinski et al., 2012) and
119 breast cancer (Alexandrov et al., 2013) genomes to annotate
mutations consistent with the APOBEC signature (i.e., TCW/
TGWor TCW/TTW).We also identifiedmutation clusters based
on inter-mutation distance, excluding complex mutations as
described earlier (Roberts et al., 2012, 2013). Similar to prior ob-
servations (Alexandrov et al., 2013; Nik-Zainal et al., 2012; Rob-
erts et al., 2012, 2013), strand-coordinated clusters in which
all mutations occurred in either cytosines (C-coordinated) or in
guanines (G-coordinated) of the same strand were highly en-
riched with APOBEC-signature mutations. Clusters of three or
more mutations all displayed equally high APOBEC enrichment
regardless of the number of mutations, indicating that they con-
tained at most a small fraction of incidental non-APOBEC muta-1104 Cell Reports 13, 1103–1109, November 10, 2015 ª2015 The Authorstions (Figure S1). We next examined the
genomic positions of these APOBEC-
enriched C- or G-coordinated clusters
relative to replication timing and chro-
matin accessibility (Figure 1) and found a
high abundance of such clusters in the
early-replicating regions of the genomes,
which preferentially contain accessiblechromatin and active transcription. This observed distribution
of APOBEC-induced mutations in relationship to replication
timing is reversed compared to the known distribution of most
other somatic mutations in cancer, which have been shown to
be prevalent in late-replicating heterochromatinized regions of
the genome (Donley and Thayer, 2013; Koren et al., 2012; Law-
rence et al., 2013; Liu et al., 2013; Polak et al., 2014; Schuster-
Bo¨ckler and Lehner, 2012; Sima and Gilbert, 2014).
Similar to Clustered Mutations, Scattered
APOBEC-Signature Mutations Show Elevated Density in
Early-Replicating Regions
Next, we inquired whether the genome-wide distribution of all
APOBEC-induced mutations relative to replication timing and
chromatin accessibility would be similar to that observed for
clustered mutations. While not all mutations consistent with the
APOBEC signature are actually induced by APOBEC, samples
with higher enrichments of the APOBEC signature will contain
greater fractions of mutations that in fact have been induced
by APOBEC. Thus, the APOBEC-signature mutations in samples
with high enrichment would more accurately depict the genome-
wide distribution of APOBEC mutagenesis. We therefore calcu-
lated the enrichment of individual samples with the APOBEC
signature mutations as described before (Roberts et al., 2013)
to determine the extent to which APOBEC enzymes were
operating in a given sample. We analyzed the distribution of
APOBEC-signature mutations with respect to replication timing
and chromatin accessibility using linear regression. We found
that regression coefficients (i.e., slopes of the regression lines)
Figure 2. Dependence of the Normalized Density of APOBEC-Signature Mutations from Replication Timing of a Cancer Genome Region
(A and B) Samples with low or no enrichment with APOBECmutation signature (fold enrichment < 2) display a positive correlation between the normalized density
of APOBEC-signature mutations and replication timing (an example for lung cancer is shown in A, and an example for breast cancer is shown in B).
(C and D) Samples with high enrichment with APOBECmutation (fold enrichmentR 2) display a negative correlation between the normalized density of APOBEC-
signature mutations and replication timing (an example for lung cancer is shown in C, and an example for breast cancer is shown in D).
Bins on the horizontal axes in (A)–(D) were obtained by sorting all genome positions by the values of a genomic feature (DNA replication time or chromatin
accessibility) and then dividing into ten non-overlapping, equal-sized windows.
(E and F) In general, the slopes of this regression are anti-correlatedwith APOBEC-signature enrichment (lung cancer data are shown in E, and breast cancer data
are shown in F). Similar analyses with respect to chromatin accessibility are shown in Figure S2, and analyses performed separately for the two subcategories of
APOBEC-signature mutations (TCW/TTW and TCW/TGW) are shown in Figure S3. The sample-specific enrichment values used for the analyses in Figures 2
and S3 are shown in Table S1.are inversely proportional to the APOBEC sample enrichment
(Figures 2 and S2), indicating that the density of mutations
actually induced by APOBEC increases in early-replicating,Cell Repchromatin-accessible regions. This inverse proportionality was
invariably observed, even when the two subcategories of
APOBEC-signature mutations (TCW/TTW and TCW/TGW)orts 13, 1103–1109, November 10, 2015 ª2015 The Authors 1105
Figure 3. Increased Density of the APOBEC-Signature Mutations in Early-Replicating Regions of Genome Is Confirmed by the Linear Model
Considering Heterogeneity of Mutational Mechanisms and by the Analysis of Mutations in Multiple Exomes of Several Cancer Types
(A) The dependency of APOBEC-induced mutation density (inferred from the linear model that allows for heterogeneity of mutational mechanisms; see
Experimental Procedures) on replication timing and on APOBEC-signature mutation enrichment in lung cancer samples. DNA replication time is presented in
ENCODE units ofmeasure, linearly scaled in the range [0 to 90] and binned as in Figure 2. The vertical axis showsmutation density per 10Mwindow, calculated as
a number of mutations in the window normalized by a number of TCW motifs in the window and by a total number of mutations in the sample (see formula in
Experimental Procedures). See Table S2 for all calculated model parameters.
(B) The median of differences in APOBEC-signature mutation enrichments between early- and late-replicating regions of exomes from samples of six types of
cancer in which an enrichment with the APOBEC mutation signature was statistically significant in both early- and late-replicating regions. Cancer types are
abbreviated as in TCGA: bladder urothelial carcinoma (BLCA), breast invasive carcinoma (BRCA), cervical squamous cell carcinoma and endocervical
adenocarcinoma (CESC), head and neck squamous cell carcinoma (HNSC), lung adenocarcinoma (LUAD), and lung squamous cell carcinoma (LUSC). *p < 0.05;
**p < 0.01; ***p < 0.001. Exact values: PBLCA = 0.0011, PBRCA = 0.038, PCESC = 0.023, PHNSC = 0.49, PLUAD = 0.0028, and PLUSC = 0.0007.were analyzed separately (Figure S3). All sample-specific enrich-
ment values used in the analyses are listed in Table S1.
To extend the model into all samples and to take into account
C/T and C/G mutations occurring in the TCW motif, but
induced by other mutagens, we introduced a linear model that
explicitly allows for two classes of APOBEC-signature muta-
tions: mutations induced by APOBECandmutations due to other
mechanisms. The regression coefficient for mutations actually
induced by APOBEC is a free parameter of this model. This
model allows us to infer the dependency of mutations in fact
induced by APOBEC on epigenomic variables. This analysis is
conservative because it assumes that APOBEC never induces
mutations outside of the motif. As shown in Figure 3A (see also
Table S2), these mutations show a strong preference toward
early-replicating regions (all P values for replication timing and
chromatin accessibility of lung and breast cancer are below
0.001; see exact values in Table S2). Collectively, our observa-
tions establish that the distribution of APOBEC-induced muta-
tions in cancer genomes is reversed in comparison to the bulk
of mutations produced by other mechanisms.
APOBEC-Signature Mutations in the Exomes from
the Cancer Genome Atlas Are More Prevalent in
Early-Replicating Regions
In addition to the exploration of whole-genome sequenced
(WGS) cancer samples, we applied our analysis to a large data-
set of somatic mutations that occurred in the exomes of six
cancer types known to be highly mutated by APOBEC en-
zymes (Roberts et al., 2013) (obtained from the TCGA; Broad
GDAC Firehose standard data run of February 15, 2014; http://
gdac.broadinstitute.org/runs/stddata__2014_02_15/). Although,1106 Cell Reports 13, 1103–1109, November 10, 2015 ª2015 The Auexomes constitute only around 1%of the genome, the number of
sequenced exomes in The Cancer Genome Atlas (TCGA) is large
in comparison with the number of available complete cancer ge-
nomes. For this simplified analysis we used two genome tracks
identified as universally early- or universally late-replicating re-
gions, based on available replication timing data for multiple
cell types (Pedersen et al., 2013). We then created two lists of
mutation calls falling into each of these tracks and calculated
the enrichments with APOBEC-signature for the two groups of
mutations of each sample. Samples with statistically significant
APOBEC enrichment for both early- and late-replicating regions
were used to evaluate the impact of replication timing. In agree-
mentwith the results forWGSanalysis, theAPOBECenrichments
for mutation calls falling into early-replicating regions exceeded
enrichments for calls from late-replicating regions for breast
and lung cancers as well as for two other cancer types, cervical
and bladder carcinomas (Figure 3B). We note that the lack of a
statistically significant difference for head and neck squamous
cell carcinomas could be due to its small sample size within the
exomemutation catalog or could reflect differences in themech-
anisms underlying APOBEC mutagenesis in this cancer type.
The Observed Genome Distribution of APOBEC-
Signature Mutations between Early- and Late-
Replicating Regions Is Not Affected by Transcription
Because ssDNA associated with transcription is an established
target of several activation-induced cytidine deaminase (AID)/
APOBEC family members and early-replication regions are
also gene dense, we examined whether the enrichment of
APOBEC-induced mutations in these regions could be depen-
dent on transcription. To this end, we compared the distributionthors
Figure 4. The Anti-correlation between the Density of APOBEC-Signature Mutation and Replication Timing in Cancer Genomes Is Inde-
pendent on Transcription
(A–D) Anti-correlation of APOBEC enrichment versus replication timing regression slopes in samples with different APOBEC-signature enrichment determined
separately for transcribed and non-transcribed regions of the lung (A) and breast (B) cancer genomes and for transcribed and non-transcribed strands of DNA in
the lung (C) and breast (D) cancer genomes, including only samples with statistically significant enrichment with APOBEC mutation signature. Exact p values: (A)
0.055, (B) 0.34, (C) 0.14, and (D) 0.17. See Figure S4 for a similar comparison including all samples.of APOBEC-signature mutations to replication timing separately
for transcribed and non-transcribed regions of the genome.
APOBEC-induced mutations predominated in early-replicating
regions of the genome for non-transcribed as well as transcribed
regions with no detectable difference between the two trends
(Figures 4A and 4B). Within transcribed regions, the distribution
of APOBEC-signature mutations between early- and late-repli-
cating regions was also similar between transcribed and non-
transcribed strands of DNA (Figures 4C and 4D). These results
held when the analysis was repeated with all samples, including
those without a statistically significant enrichment of the
APOBEC mutation signature, with one exception—a minor dif-
ference between transcribed and non-transcribed strands for
breast cancer (Figure S4).
DISCUSSION
Altogether, our results indicate that APOBEC-inducedmutations
occur preferentially in early-replicating regions, which them-
selves are enriched with active chromatin. We suggest that the
main cause of the observed effect is the necessity for DNA to
be in a single-stranded state in order to be mutated by APOBEC
enzymes. One source of ssDNA in early-replicating regions
could be simply the higher levels of transcription in these areas.
The APOBEC relative, AID, is known to require transcription toCell Repmediate immunoglobulin hypermutation in B cells (reviewed in
Liu and Schatz, 2009), and both AID and APOBEC3G in yeast
appear to target transcription when expressed in yeast (Taylor
et al., 2014). However, our analysis shows that the density of
APOBEC-signature mutations was equal between transcribed
and non-transcribed regions (Figures 4 and S4), which suggests
that replication timing could be the primary factor affecting the
chance of cytidine deamination by one of the APOBEC enzymes.
The dependence on replication timing appears robust and uni-
versal. It was detectable even in the exome datasets of five out of
six cancer types known to have a high presence of APOBEC
mutagenesis and even when only universally late- or universally
early-replicating regions were used in the analysis (Figure 3B).
We speculate that increased DNA fragility in early-replicating re-
gions may produce more ssDNA substrate for APOBEC en-
zymes. Early-replicating, highly transcribed regions of cancer
genomes are known to be associated with changes stemming
from chromosome breakage, such as copy-number variation,
chromosome rearrangements, fragility, and loss of heterozygos-
ity (Barlow et al., 2013; Koren et al., 2012; Pedersen and De,
2013; Sima and Gilbert, 2014). An increased frequency of
DNA breakage would in turn be expected to produce more hy-
permutable ssDNA as the repair of these breaks often involves
formation of ssDNA through either 50/30 resection (Mimitou
and Symington, 2011; Roberts et al., 2012) or uncoupledorts 13, 1103–1109, November 10, 2015 ª2015 The Authors 1107
conservative replication (Malkova and Ira, 2013; Saini et al.,
2013; Sakofsky et al., 2014). Consistent with this idea, ssDNA
formed during DNA double-strand break repair is prone to
DNA-damage-induced mutation in yeast model systems. Addi-
tionally, APOBEC mutagenesis in cancer is increased in the
vicinity of chromosome rearrangement breakpoints (Drier et al.,
2013; Nik-Zainal et al., 2012; Roberts et al., 2012).
While a mechanistic explanation for the correlation between
the location of APOBEC mutations and structural alternations in
cancer genomes remains to be established, we propose that
these events may originate from a common source relating to
replication timing. Importantly, the targeting of APOBEC-induced
mutations to early-replicating regions appears to be a distinct
mechanism from the specific localization of the AID to active pro-
moters and super-enhancers during B cell transcription (Meng
et al., 2014; Qian et al., 2014). In activated B cells, AID-induced
double-strand breaks (DSBs) and kataegic sites associate with
a relatively small number of transcribed promoters and en-
hancers (Meng et al., 2014; Qian et al., 2014), resulting in a limited
over-representation of the AID signature motif (WRC, where W =
A or T and R = G or A) among all mutations in B-cell-derived tu-
mors and no observed AID activity in other tumor types (Alexan-
drov et al., 2013). In contrast, APOBEC-inducedmutations occur
in greater abundance and widely spread across cancer ge-
nomes, without an apparent preference to any regulatory se-
quences. Reportedly, < 6%ofAPOBEC-induced kataegic events
occur near transcriptional start sites compared to 82% for AID-
induced events (Qian et al., 2014), while APOBECs favor early-
replicating regions of the genome, which, in B cells, are devoid
of AID-induced DSBs (Barlow et al., 2013).
It remains to establish the specific cellular processes account-
ing for the unique correlation of APOBEC mutagenesis with
gene-dense early-replicating regions of active chromatin; how-
ever, this association could already be used in the search for
genes significantly mutated in cancers to accurately define
background mutation rates for APOBEC-signature mutations
specific to genomic regions of interest (Lawrence et al., 2013).
EXPERIMENTAL PROCEDURES
The mutation data for 24 lung adenocarcinomas are from Imielinski et al.
(2012), and mutation data for 119 breast cancers are from Alexandrov et al.
(2013). We annotated mutation clusters as well as APOBEC-signature muta-
tions as described previously (Roberts et al., 2013). Briefly, mutation clusters
were identified and mutation signatures assigned after filtering out mutations
(usually < 10%of total) falling within regions identified as simple repeats in sim-
pleRepeat.txt.gz from http://hgdownload.cse.ucsc.edu/goldenPath/hg19/
database/. Additionally, groups of very closely (10 nt or less) spaced mutation
events, which are often caused by single act of synthesis by error-prone poly-
merase, were counted as a singlemutation event. The TCWAPOBECmutation
signature was defined as TCW/TTW or TCW/TGW mutation events.
Enrichment with APOBEC mutation signature was calculated as an overrepre-
sentation of the signature compared to random mutagenesis as in Roberts
et al. (2013).
We used epigenomic data generated by the ENCODE project (Raney et al.,
2011). For the analysis of lung cancer and breast cancer genomes, we used
DNA replication timing for IMR90 andMCF-7 cell lines, and DNase I hypersen-
sitivity data obtained for A549 and MCF-7 cell lines, respectively. A single-
sample distribution of the APOBEC-induced mutation density relative to
genomic features was estimated by a simple linear regression model, where
a particular genomic feature was considered as the only independent variable.1108 Cell Reports 13, 1103–1109, November 10, 2015 ª2015 The AuThe independent variable was sampled as follows: all genome positions were
sorted by the values of the genomic feature and then divided into ten adjacent
non-overlapped equal-sized windows (bins). The number of APOBEC-signa-
ture mutations in a window was normalized by the number of TCW motifs in
a bin and by the total number of APOBEC-signature mutations in a sample
(referred to as the normalized density throughout this paper).
In amulti-sample linear regressionmodel of genome-wide mutation density,
we considered separately APOBEC and backgroundmutagenesis. This model
was defined as follows:
Mðx; sÞ 

aðsÞðbA0 + bA1fðxÞÞ+ ð1 aðsÞÞðbN0 +bN1fðxÞÞ; if x ˛ TCW
bN0 + bN1fðxÞ; if x; TCW
where x is genomic position; f(x) is the value of epigenomic feature at x; a(s) is
the fraction of APOBEC-induced mutations in a sample as estimated from the
APOBEC-signature mutation enrichment of the sample s: a(s) = 1  1/e(s); bA0
and bA1 are model coefficients corresponding to mutations that were in fact
induced by APOBEC; bN0 and bN1 are coefficients corresponding to mutations
not caused by APOBEC independently of the presence of the APOBEC signa-
ture; and M is the mutation density calculated as the number of mutations in
the window normalized by the number of TCW motifs in a window and by
the total number ofmutations in a sample. The number ofmutations and values
of genomic features were respectively summed or averaged over 10 M non-
overlapping windows along the genome. The results for smaller window sizes
are qualitatively similar.
Somatic mutations in exomes were obtained from TCGA (Broad GDAC Fire-
hose standard data run of February 15, 2014; http://gdac.broadinstitute.org/
runs/stddata__2014_02_15/). Each nucleotide position with the exomes was
classified into early- or late-replication region according to Pedersen et al.
(2013). Enrichment of APOBEC-signature mutations in early- and late-repli-
cating regions was calculated separately and as described before (Roberts
et al., 2013). Samples with statistically insignificant APOBEC enrichment in
any replicating regions were excluded from this analysis.
A statistical significance of the difference between transcribed and non-
transcribed regions and strands was calculated as follows: data from different
regions or strand were merged with introduction of the indicator variable
describing a source of the data. A linear regression was calculated, and the
value of statistical significance was extracted from the regression results as
the significance of the coefficient relating to the indicator variable.
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